Log in

Diplomat Pharmacy Stock Price, News & Analysis (NYSE:DPLO)

$4.69
+0.10 (+2.18 %)
(As of 10/16/2019 08:08 AM ET)
Today's Range
$4.55
Now: $4.69
$4.72
50-Day Range
$4.52
MA: $5.39
$6.60
52-Week Range
$4.17
Now: $4.69
$21.48
Volume424,028 shs
Average Volume687,514 shs
Market Capitalization$355.64 million
P/E Ratio23.45
Dividend YieldN/A
Beta0.99
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. Read More…

Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorRetail/Wholesale
CUSIPN/A
Phone888-720-4450

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.49 billion
Cash Flow$4.60 per share
Book Value$6.24 per share

Profitability

Net Income$-302,270,000.00

Miscellaneous

Employees2,335
Market Cap$355.64 million
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive DPLO News and Ratings via Email

Sign-up to receive the latest news and ratings for DPLO and its competitors with MarketBeat's FREE daily newsletter.


Diplomat Pharmacy (NYSE:DPLO) Frequently Asked Questions

What is Diplomat Pharmacy's stock symbol?

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

How were Diplomat Pharmacy's earnings last quarter?

Diplomat Pharmacy Inc (NYSE:DPLO) released its quarterly earnings data on Friday, August, 9th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01. The business earned $1.29 billion during the quarter, compared to the consensus estimate of $1.23 billion. Diplomat Pharmacy had a negative net margin of 8.93% and a negative return on equity of 4.01%. The firm's quarterly revenue was down 9.1% on a year-over-year basis. During the same period last year, the business posted ($0.05) earnings per share. View Diplomat Pharmacy's Earnings History.

When is Diplomat Pharmacy's next earnings date?

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Diplomat Pharmacy.

What guidance has Diplomat Pharmacy issued on next quarter's earnings?

Diplomat Pharmacy updated its FY19 earnings guidance on Friday, August, 9th. The company provided earnings per share guidance of ($2.69-2.55) for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($0.54). The company issued revenue guidance of $4.7-5.0 billion, compared to the consensus revenue estimate of $4.91 billion.

What price target have analysts set for DPLO?

14 Wall Street analysts have issued 12-month target prices for Diplomat Pharmacy's shares. Their forecasts range from $4.00 to $30.00. On average, they expect Diplomat Pharmacy's share price to reach $9.65 in the next twelve months. This suggests a possible upside of 105.8% from the stock's current price. View Analyst Price Targets for Diplomat Pharmacy.

What is the consensus analysts' recommendation for Diplomat Pharmacy?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 3 sell ratings, 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Diplomat Pharmacy.

Has Diplomat Pharmacy been receiving favorable news coverage?

News headlines about DPLO stock have trended very negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Diplomat Pharmacy earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an effect on the company's share price in the near future. View News Stories for Diplomat Pharmacy.

Are investors shorting Diplomat Pharmacy?

Diplomat Pharmacy saw a drop in short interest in the month of September. As of September 15th, there was short interest totalling 7,680,000 shares, a drop of 7.6% from the August 15th total of 8,310,000 shares. Based on an average daily trading volume, of 790,800 shares, the short-interest ratio is currently 9.7 days. Currently, 13.3% of the shares of the company are sold short. View Diplomat Pharmacy's Current Options Chain.

Who are some of Diplomat Pharmacy's key competitors?

What other stocks do shareholders of Diplomat Pharmacy own?

Who are Diplomat Pharmacy's key executives?

Diplomat Pharmacy's management team includes the folowing people:
  • Mr. Brian Thomas Griffin, CEO & Chairman (Age 60)
  • Mr. Philip R. Hagerman, Co-Founder & Chairman Emeritus (Age 67)
  • Mr. Daniel Paul Davison, CFO & Treasurer
  • Mr. Dave Loschinskey, Chief Operating Officer (Age 48)
  • Ms. Terri Anne Powers, VP of Investor Relations

Who are Diplomat Pharmacy's major shareholders?

Diplomat Pharmacy's stock is owned by a number of of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.06%). Company insiders that own Diplomat Pharmacy stock include Atul Kavthekar, Jeffrey G Park, Joel Saban, Kenneth O Klepper, Philip R Hagerman, Regina M Benjamin and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.

Which institutional investors are buying Diplomat Pharmacy stock?

DPLO stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy.

How do I buy shares of Diplomat Pharmacy?

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Diplomat Pharmacy's stock price today?

One share of DPLO stock can currently be purchased for approximately $4.69.

How big of a company is Diplomat Pharmacy?

Diplomat Pharmacy has a market capitalization of $355.64 million and generates $5.49 billion in revenue each year. The company earns $-302,270,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Diplomat Pharmacy employs 2,335 workers across the globe.View Additional Information About Diplomat Pharmacy.

What is Diplomat Pharmacy's official website?

The official website for Diplomat Pharmacy is http://www.diplomatpharmacy.com/.

How can I contact Diplomat Pharmacy?

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]


MarketBeat Community Rating for Diplomat Pharmacy (NYSE DPLO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  331 (Vote Outperform)
Underperform Votes:  355 (Vote Underperform)
Total Votes:  686
MarketBeat's community ratings are surveys of what our community members think about Diplomat Pharmacy and other stocks. Vote "Outperform" if you believe DPLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DPLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel